A detailed history of Avoro Capital Advisors LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 6,875,000 shares of RNA stock, worth $300 Million. This represents 4.75% of its overall portfolio holdings.

Number of Shares
6,875,000
Previous 6,505,000 5.69%
Holding current value
$300 Million
Previous $266 Million 18.83%
% of portfolio
4.75%
Previous 3.63%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $13.8 Million - $17.8 Million
370,000 Added 5.69%
6,875,000 $316 Million
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $15.5 Million - $27.8 Million
680,000 Added 11.67%
6,505,000 $266 Million
Q1 2024

May 15, 2024

BUY
$9.16 - $25.52 $30.4 Million - $84.6 Million
3,315,000 Added 132.07%
5,825,000 $149 Million
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $7.06 Million - $11.8 Million
460,000 Added 22.44%
2,510,000 $38.5 Million
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $6.04 Million - $13.6 Million
600,000 Added 41.38%
2,050,000 $45.5 Million
Q3 2022

Nov 14, 2022

BUY
$15.46 - $23.43 $2.32 Million - $3.51 Million
150,000 Added 11.54%
1,450,000 $23.7 Million
Q1 2022

May 16, 2022

BUY
$14.2 - $23.78 $994,000 - $1.66 Million
70,000 Added 5.69%
1,300,000 $24 Million
Q4 2021

Feb 14, 2022

BUY
$20.4 - $28.66 $1.63 Million - $2.29 Million
80,000 Added 6.96%
1,230,000 $29.2 Million
Q3 2021

Nov 15, 2021

BUY
$18.16 - $25.21 $11 Million - $15.3 Million
605,000 Added 111.01%
1,150,000 $28.3 Million
Q3 2020

Nov 16, 2020

SELL
$23.35 - $35.94 $934,000 - $1.44 Million
-40,000 Reduced 6.84%
545,000 $15.3 Million
Q2 2020

Aug 14, 2020

BUY
$26.62 - $31.5 $15.6 Million - $18.4 Million
585,000 New
585,000 $16.5 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.28B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Avoro Capital Advisors LLC Portfolio

Follow Avoro Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.